Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Market Closed - Nasdaq Other stock markets 01:30:00 17/05/2024 am IST			5-day change	1st Jan Change
8.9 ^USD	+0.34%		+15.28%	-20.89%

09/05	Transcript : Altimmune, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Earnings Flash (ALT) ALTIMMUNE Reports Q1 Revenue $5,000	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Altimmune Shares Decline After Guggenheim Downgrade	29/04	MT
Guggenheim Downgrades Altimmune to Neutral From Buy	29/04	MT
B. Riley Raises Altimmune's PT to $20 From $15 on Increased Obesity+NASH Therapeutics' Product Sales Projections; Keeps Buy Rating	17/01	MT
B. Riley Lowers Altimmune's PT to 8 From $15, Says Updated Model Adjusts for Ongoing Obesity+NASH Market Dynamics; Maintains Buy Rating	09/11	MT
HC Wainwright Adjusts Price Target on Altimmune to $15 From $50, Maintains Buy Rating	14/23/14	MT
B. Riley Lowers Altimmune's Price Target to $15 From $20, Keeps Buy Rating	11/23/11	MT
B. Riley Lowers Altimmune's Price Target to $20 From $26, Keeps Buy Rating	10/23/10	MT
Goldman Sachs Downgrades Altimmune to Neutral From Buy, Adjusts Price Target to $6 From $20	22/23/22	MT
HC Wainwright Reiterates Altimmune at Buy With $50 Price Target	20/23/20	MT
Evercore ISI Adjusts Altimmune Price Target to $25 From $14, Maintains Outperform Rating	18/23/18	MT
Goldman Sachs Initiates Altimmune at Buy With $20 Price Target	01/22/01	MT
JMP Securities Adjusts Price Target on Altimmune to $26 From $28, Maintains Market Outperform Rating	11/22/11	MT
Guggenheim Adjusts Altimmune's Price Target to $26 From $31, Reiterates Buy Rating	16/22/16	MT
Jefferies Adjusts Altimmune's Price Target to $35 From $30, Reiterates Buy Rating	31/22/31	MT
HC Wainwright Adjusts Altimmune's Price Target to $50 From $25, Reiterates Buy Rating	17/22/17	MT
B. Riley Securities Raises Altimmune's Price Target to $26 from $21, Increases Likelihood of Technical, Regulatory Success; Keeps Buy Rating	12/22/12	MT
Piper Sandler Adjusts Altimmune's Price Target to $25 From $34, Reiterates Overweight Rating	18/22/18	MT
Guggenheim Adjusts Altimmune's Price Target to $28 From $33, Reiterates Buy Rating	16/22/16	MT
B. Riley Lowers Altimmune's Price Target to $21 from $27 After Revising Cost Capital Assumptions, Keeps Buy Rating	24/22/24	MT
ALTIMMUNE : Piper Sandler Adjusts Altimmune's Price Target to $34 from $16, Keeps Overweight Rating	08/21/08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Altimmune, Inc.

Equities

ALT

US02155H2004

Analyst Reco.

Filters